ClinicalTrials.gg
TerminatedNCT02222207DREAMUpdated Sep 8, 2016Results posted

Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration

A Phase 2 interventional study of Regorafenib, ophthalmic oily suspension (BAY73-4506) and Sham IVT in Macular Degeneration, sponsored by Bayer. Terminated at 149 sites in 18 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2016-09-08.

Sponsored by Bayer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Macular Degeneration by Bayer — none open to participants now, 1 under way, none of them phase 3. Macular Degeneration · Bayer.

Enrollment
8th of 10
52 · median 296
Started
2014
with 3 others
Phase 2
Only one
of the 30
Registered
11th of 30
by date

Among the 30 studies in Macular Degeneration by Bayer, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is one of 4 that started in 2014, is the only one in phase 2, and was the 11th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

None of the 30 studies in Macular Degeneration by Bayer is open now. The open studies under Macular Degeneration, anywhere →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 30 studies in Macular Degeneration by Bayer as a file.
02

Study summary

Part A (Phase IIa):

Primary objectives:

The study part A is designed to investigate whether the use of regorafenib eye drops can help patients with neovascular (wet) Age-Related Macular Degeneration (wAMD) to see better after 4 weeks and 12 weeks after inclusion into this study.

Secondary objectives:

The study will also evaluate the safety and tolerability of the regorafenib eye drops.

Part B (Phase IIb):

Primary objectives:

The study part B is designed to investigate:

  • how often the regorafenib eye drops need to be given per day
  • whether the use of regorafenib eye drops can help patients with neovascular (wet) Age-Related Macular Degeneration (wAMD) to see better after 4 weeks and 12 weeks after inclusion into this study.

Secondary objectives:

The study will also evaluate how the different dosings of regorafenib eye drops affect patients vision, the safety and the tolerability.

03

Conditions studied

  • Macular Degeneration

Keywords

  • neovascular Age-related Macular Degeneration
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to read (or, if unable to read due to visual impairment, be read to verbatim by the person administering the or a family member) and able to understand the informed consent form (ICF)
  • Men and women ≥ 50 years of age
  • Active primary subfoveal CNV (Choroidal neovascularization) lesions secondary to AMD (Age-related macular degeneration), including juxtafoveal lesions that affect the fovea as evidenced by FA (Fluorescein angiography) in the study eye and reviewed by the central reading center
  • The area of CNV must occupy at least 50% of total lesion in the study eye, as determined by FA review at the central reading center
  • Evidence of intraretinal and/or subretinal fluid on OCT (Optical coherence tomography)
  • Early Treatment Diabetic Retinopathy Study BCVA of 73 to 25 letters (20/40 to 20/320 Snellen equivalent) in the study eye
  • Willing, committed, and able to return for all clinic visits and complete all study related procedures
  • Women of and men must agree to use adequate when sexually active. This applies since signing of the ICF until one month after the EOS (end of study) visit. The definition of adequate contraception will be based on the judgment of the investigator.

Exclusion criteria

Exclusion Criteria:

  • Concurrent disease in the study eye, other than AMD (e.g., corneal diseases and dystrophies, conjunctival diseases, eye lid abnormalities, or any other diseases of the cornea and macula, or optic nerve abnormality) that could compromise visual acuity, likely require medical or surgical intervention during the study period, would limit the potential to gain or lose vision during study treatment, or could otherwise confound interpretation of the results
  • Total lesion size (including neovascularization, scar, blood) > 12 disc areas (30.5 mm2) as assessed by FA
  • Only one functional eye, even if that eye is otherwise eligible for the study
  • Prior ocular or systemic treatment or surgery for neovascular AMD in the study eye except dietary supplements or vitamins
  • Prior treatment with any systemic anti-VEGF (Vascular endothelial growth factor) agent
  • Use of systemic or ocular treatment with an drug within 12 weeks prior to start of study treatment
  • Any other condition that would require frequent chronic co-administration of other topical eye medications that would interfere with study drug administration (e.g. contact lens)
  • Symptoms or conditions consistent with listed in the current local label for ranibizumab
  • Participation in an investigational study within 30 days prior to start of study treatment that involved treatment with any drug (excluding vitamins and minerals) or device
  • Lactating women and women of with either a positive pregnancy test result or no pregnancy test at screening are excluded. women must be amenorrheic for at least 12 months in order not to be considered of child bearing potential.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Regorafenib [A]

    Part A: Patients will receive Regorafenib eye drops

    Drug: Regorafenib, ophthalmic oily suspension (BAY73-4506)

  • Experimental
    Regorafenib [B1]

    Part B: Regorafenib eye drops dose 1; plus sham IVT (Intravitreal therapy) once every 4 weeks

    Drug: Regorafenib, ophthalmic oily suspension (BAY73-4506) · Procedure: Sham IVT

  • Experimental
    Regorafenib [B2]

    Part B: Regorafenib eye drops dose 2; plus sham IVT (Intravitreal therapy) once every 4 weeks

    Drug: Regorafenib, ophthalmic oily suspension (BAY73-4506) · Procedure: Sham IVT

  • Experimental
    Regorafenib [B3]

    Part B: Regorafenib eye drops dose 3; plus sham IVT (Intravitreal therapy) once every 4 weeks

    Drug: Regorafenib, ophthalmic oily suspension (BAY73-4506) · Procedure: Sham IVT

  • Experimental
    Regorafenib [B4]

    Part B: Regorafenib eye drops dose 4; plus sham IVT (Intravitreal therapy) once every 4 weeks

    Drug: Regorafenib, ophthalmic oily suspension (BAY73-4506) · Procedure: Sham IVT

  • Experimental
    Regorafenib [B5]

    Part B: Regorafenib eye drops dose 5; plus sham IVT (Intravitreal therapy) once every 4 weeks

    Drug: Regorafenib, ophthalmic oily suspension (BAY73-4506) · Procedure: Sham IVT

  • Experimental
    Regorafenib [B6]

    Part B: Regorafenib eye drops dose 6; plus sham IVT (Intravitreal therapy) once every 4 weeks

    Drug: Regorafenib, ophthalmic oily suspension (BAY73-4506) · Procedure: Sham IVT

  • Active comparator
    Ranibizumab

    Ranibizumab IVT once every 4 weeks; plus placebo eye drops to match the regorafenib eye drop regimens

    Drug: Ranibizumab · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Study Week 4 for Study Part A

    Participants will be assessed at each clinic visit for best corrected visual acuity using the early treatment diabetic retinopathy study chart. Visual function of the study eye and the fellow eye was assessed using the ETDRS. The participant's ETDRS testing score was recorded in the appropriate eCRF page at each study visit. For participants that dropped out or received rescue treatment the last observation before drop-out or administration of rescue treatment was carried forward. A higher score represents better functioning.

    Time frame: Baseline, Week 4

  2. Change From Baseline in BCVA as Measured by ETDRS Letter Score at Study Week 12 for Study Part A

    Participants were assessed at each clinic visit for best corrected visual acuity using the early treatment diabetic retinopathy study chart. Visual function of the study eye and the fellow eye was assessed using the ETDRS protocol. ETDRS testing score was recorded in the appropriate eCRF page at each study visit. For participants that dropped out or received rescue treatment the last observation before drop-out or administration of rescue treatment was carried forward. A higher score represents better functioning.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Percentage of Participants With Individual Changes in BCVA of Greater Than Equal to (>=) 0 Letters of Vision From Study Week 4 to Week 12 for Study Part A

    Participants were assessed at each clinic visit for BCVA using the early treatment diabetic retinopathy study chart. For participants that dropped out or received rescue treatment the last observation before drop-out or administration of rescue treatment was carried forward.

    Time frame: Week 4, Week 12

  2. Percentage of Participants With a Loss in BCVA of >= 10 Letters From Baseline to Study Week 12 for Study Part A

    Participants were assessed at each clinic visit for BCVA using the early treatment diabetic retinopathy study chart. For participants that dropped out or received rescue treatment the last observation before drop-out or administration of rescue treatment was carried forward.

    Time frame: Baseline, Week 12

07

Results

Posted Sep 8, 2016
Limitations and caveats
As the study was prematurely terminated since pre-defined proof of concept (PoC) criteria were not met in Part A, hence part B was not initiated. Part B related end points and data were not reported since it is not conducted.

Participant flow

The study was conducted at 27 centers, between 10 October 2014 (first subject first visit) and 17 June 2015 (last subject last visit).

Participant flow — Overall Study
MilestonePart A Regorafenib
Started52
Treated and valid for full analysis set51
Completed48
Not completed4
Withdrew: Death1
Withdrew: Other reasons2
Withdrew: Adverse event1

Outcome measures

PrimaryChange From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Study Week 4 for Study Part A

Participants will be assessed at each clinic visit for best corrected visual acuity using the early treatment diabetic retinopathy study chart. Visual function of the study eye and the fellow eye was assessed using the ETDRS. The participant's ETDRS testing score was recorded in the appropriate eCRF page at each study visit. For participants that dropped out or received rescue treatment the last observation before drop-out or administration of rescue treatment was carried forward. A higher score represents better functioning.

Time frame:
Baseline, Week 4
Reported as:
Mean · Score on scale
Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Study Week 4 for Study Part A
Score on scalePart A Regorafenib
Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Study Week 4 for Study Part A1.18 ± 7.55
PrimaryChange From Baseline in BCVA as Measured by ETDRS Letter Score at Study Week 12 for Study Part A

Participants were assessed at each clinic visit for best corrected visual acuity using the early treatment diabetic retinopathy study chart. Visual function of the study eye and the fellow eye was assessed using the ETDRS protocol. ETDRS testing score was recorded in the appropriate eCRF page at each study visit. For participants that dropped out or received rescue treatment the last observation before drop-out or administration of rescue treatment was carried forward. A higher score represents better functioning.

Time frame:
Baseline, Week 12
Reported as:
Mean · Score on scale
Change From Baseline in BCVA as Measured by ETDRS Letter Score at Study Week 12 for Study Part A
Score on scalePart A Regorafenib
Change From Baseline in BCVA as Measured by ETDRS Letter Score at Study Week 12 for Study Part A-2.36 ± 7.68
SecondaryPercentage of Participants With Individual Changes in BCVA of Greater Than Equal to (>=) 0 Letters of Vision From Study Week 4 to Week 12 for Study Part A

Participants were assessed at each clinic visit for BCVA using the early treatment diabetic retinopathy study chart. For participants that dropped out or received rescue treatment the last observation before drop-out or administration of rescue treatment was carried forward.

Time frame:
Week 4, Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Individual Changes in BCVA of Greater Than Equal to (>=) 0 Letters of Vision From Study Week 4 to Week 12 for Study Part A
percentage of participantsPart A Regorafenib
Percentage of Participants With Individual Changes in BCVA of Greater Than Equal to (>=) 0 Letters of Vision From Study Week 4 to Week 12 for Study Part A42
SecondaryPercentage of Participants With a Loss in BCVA of >= 10 Letters From Baseline to Study Week 12 for Study Part A

Participants were assessed at each clinic visit for BCVA using the early treatment diabetic retinopathy study chart. For participants that dropped out or received rescue treatment the last observation before drop-out or administration of rescue treatment was carried forward.

Time frame:
Baseline, Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With a Loss in BCVA of >= 10 Letters From Baseline to Study Week 12 for Study Part A
percentage of participantsPart A Regorafenib
Percentage of Participants With a Loss in BCVA of >= 10 Letters From Baseline to Study Week 12 for Study Part A16

Adverse events

Collected over From the start of study treatment until 30 days after last dose of study drug treatment (up to Week 16).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A Regorafenib—3/51 (5.9%)11/51 (21.6%)
Most frequent serious events
Most frequent serious events
EventPart A Regorafenib
Acute myocardial infarctionCardiac disorders1/51
Ankle fractureInjury, poisoning and procedural complications1/51
Visual acuity tests abnormalInvestigations1/51
Most frequent other events
Most frequent other events
EventPart A Regorafenib
Visual acuity reducedEye disorders6/51
Visual acuity tests abnormalInvestigations5/51

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part A Regorafenib
Mean75 ± 8.4
Sex: Female, Male
Sex: Female, Male(Participants)Part A Regorafenib
Female29
Male22
08

Study locations

149 sites
  • Tucson, Arizona 85704, United States
  • Arcadia, California 91007, United States
  • Beverly Hills, California 90211, United States
  • Campbell, California 95008, United States
  • Costa Mesa, California 92626, United States
  • Laguna Hills, California 92653, United States
  • Mountain View, California 94040, United States
  • Santa Ana, California 92705, United States
  • Golden, Colorado 80401, United States
  • Boynton Beach, Florida 33426, United States
  • Fort Myers, Florida 33912, United States
  • Miami, Florida 33143, United States
  • Plantation, Florida 33324, United States
  • Sarasota, Florida 34239, United States
  • Stuart, Florida 34994, United States
  • Winter Haven, Florida 33880, United States
  • Decatur, Georgia 30030, United States
  • New Albany, Indiana 47150, United States
  • Leawood, Kansas 66211, United States
  • Wichita, Kansas 67226, United States
  • Louisville, Kentucky 40207, United States
  • Eunice, Louisiana 70535, United States
  • Boston, Massachusetts 02114, United States
  • Grand Rapids, Michigan 49525, United States
  • Florissant, Missouri 63031, United States
  • Teaneck, New Jersey 07666, United States
  • Asheville, North Carolina 28803, United States
  • West Mifflin, Pennsylvania 15122, United States
  • Greenville, South Carolina 29605, United States
  • Rapid City, South Dakota 57701, United States
  • Austin, Texas 78705, United States
  • Houston, Texas 77030, United States
  • McAllen, Texas 78503, United States
  • San Antonio, Texas 78240, United States
  • Temple, Texas 76508, United States
  • The Woodlands, Texas 77384, United States
  • Charlottesville, Virginia 22908, United States
  • Strathfield, New South Wales 2135, Australia
  • Sydney, New South Wales 2000, Australia
  • Westmead, New South Wales 2145, Australia
  • Nedlands, Western Australia 6009, Australia
  • Parramatta, 2150, Australia
  • Wien, 1090, Austria
  • Wien, 1130, Austria
  • Calgary, Alberta T2H 0C8, Canada
  • Edmonton, Alberta T5H 0X5, Canada
  • Vancouver, British Columbia V5Z 3N9, Canada
  • Halifax, Nova Scotia B3H 2Y9, Canada
  • London, Ontario N6A 4V2, Canada
  • Mississauga, Ontario L4W 1W9, Canada
  • Montreal, Quebec H1T 2M4, Canada
  • Montreal, Quebec H4P 2S4, Canada
  • Sherbrooke, Quebec J1J 2B8, Canada
  • Osorno, Los Lagos 5311138, Chile
  • Metropolitana, Santiago 7510168, Chile
  • Vitacura, Santiago 7650710, Chile
  • Santiago, 8380456, Chile
  • Bogota, Distrito Capital de Bogotá 0, Colombia
  • Hradec Kralove, 500 05, Czech Republic
  • Praha 2, 128 08, Czech Republic
  • Praha 4, 140 00, Czech Republic
  • Praha 7, 170 00, Czech Republic
  • Paris, Cedex 12 75557, France
  • Boredaux, 33076, France
  • Lyon, 69003, France
  • Tübingen, Baden-Württemberg 72076, Germany
  • München, Bayern 81377, Germany
  • München, Bayern 81675, Germany
  • Bonn, Nordrhein-Westfalen 53105, Germany
  • Köln, Nordrhein-Westfalen 50937, Germany
  • Münster, Nordrhein-Westfalen 48145, Germany
  • Mainz, Rheinland-Pfalz 55131, Germany
  • Dresden, Sachsen 01067, Germany
  • Dresden, Sachsen 01307, Germany
  • Leipzig, Sachsen 04103, Germany
  • Berlin, 12203, Germany
  • Hamburg, 20251, Germany
  • Hong Kong, Hong Kong
  • Kowloon, Hong Kong
  • Budapest, 1082, Hungary
  • Budapest, 1106, Hungary
  • Budapest, 1133, Hungary
  • Debrecen, 4032, Hungary
  • Pecs, 7621, Hungary
  • Afula, 1834111, Israel
  • Beer Sheva, 8410101, Israel
  • Haifa, 3109601, Israel
  • Haifa, 3436212, Israel
  • Jerusalem, 9112001, Israel
  • Kfar Saba, 4428164, Israel
  • Petah Tikva, 4941492, Israel
  • Ramat Gan, 5262000, Israel
  • Rehovot, 7610001, Israel
  • Tel Aviv, 6423906, Israel
  • Zerifin, 6093000, Israel
  • Udine, Friuli-Venezia Giulia 33100, Italy
  • Roma, Lazio 00133, Italy
  • Roma, Lazio 00198, Italy
  • Milano, Lombardia 20122, Italy
  • Milano, Lombardia 20157, Italy

Showing the first 100 of 149 sites across 18 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2014, a primary completion of May 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2016, 1 year 4 months after primary completion. A results delay was requested in Oct 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2014
First posted
Aug 21, 2014
Start
Oct 2014
Primary completionActual
May 2015
CompletionActual
Jun 2015
Results delay requested
Oct 12, 2015
Results first posted
Sep 8, 2016
Last update
Sep 8, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02222207
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Aug 21, 2014
Start date
Oct 2014
Primary completion
May 2015
Completion
Jun 2015
Results posted
Sep 8, 2016
Last update
Sep 8, 2016

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Regorafenib

Start the discussion